New Study: Lowering Dementia Risk Takes Less BrainHQ Training than Expected
11 avr. 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Researchers report a relatively small amount of brain training is required to reduce dementia risk in the Body, Brain, Life for Cognitive...
DAVOS ALZHEIMERS COLLABORATIVE FEATURED ON THE TODAY SHOW DURING WORLD ALZHEIMER’S AND HISPANIC HERITAGE MONTH
27 sept. 2022 13h11 HE
|
Davos Alzheimer's Collaborative
Washington, DC, Sept. 27, 2022 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease,was featured on the NBC...
Alzheimer's Patient Advocates Launch Free Courses Promoting Brain Health
26 mai 2022 14h37 HE
|
UsAgainstAlzheimer's
Washington, D.C., May 26, 2022 (GLOBE NEWSWIRE) -- Today UsAgainstAlzheimer’s announced the launch of The Brain Health Academy (BHA), a new series of free online courses designed in partnership with...
DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES PARTNERSHIP WITH AGA KHAN UNIVERSITY TO LAUNCH FIRST ALZHEIMER’S RESEARCH INITIATIVE IN EAST AFRICA
23 mai 2022 09h53 HE
|
Davos Alzheimer's Collaborative
GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) -- Research Will Produce Digital Cognitive Assessments and Collect Blood Samples for Gene Sequencing Models Clinical Trial Will Conduct...
DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES EARLY DETECTION INNOVATION GRANTS
23 mai 2022 09h14 HE
|
Davos Alzheimer's Collaborative
GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced the...
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
03 mai 2022 02h00 HE
|
reMYND
PRESS RELEASE reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage...
Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare Coverage Decision
15 avr. 2022 11h42 HE
|
UsAgainstAlzheimer's
Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last...
Neurological Biomarkers Market by Application, by Type, by End-use, by Region and Forecasts to 2028
06 déc. 2021 06h58 HE
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By...
Actipulse Neuroscience Announces Successful Clinical Trial Using Fast Gamma Magnetic Stimulation for the Treatment of Alzheimer's Disease
30 sept. 2021 15h00 HE
|
Actipulse Neuroscience
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Today, the results of a recent pilot clinical trial, funded by neurotech company Actipulse Neuroscience, have demonstrated that its non-invasive...
Outlook on the Neurological Diseases Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
29 avr. 2021 07h18 HE
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...